Advancement of clinical and microbiological research for diagnosis and treatment effects.


Standardised clinical trial services in pre-analytical, analytical and post-analytical procedures.


Initiation and deployment of clinical trials data base management systems.


Accredited theory based modules with practical training for clinicians and support staff.

Welcome to TASK!

About Us

TASK is a social enterprise committed to developing, testing and progressing novelty medicines, vaccines and diagnostics in various medical therapeutic areas, most notably in anti-tuberculosis drugs, aimed at improving global health care.

Since its inception in 2005, TASK has grown exponentially and diversified into six distinct independent clinical research sites; a mycobacteriology bio-safety level 3 laboratory; a phase I to II clinical trial hospital with twenty-four beds; two registered dispensing pharmacies; a data management centre; regulatory, quality control and compliance office and a clinical research training academy.

Over the last 15 years, TASK has completed multiple research projects, many of global significance and contributed to progressing the scientific field of TB medicine and vaccine development, most notably with early bactericidal activity (EBA) studies and clinical trials that in part led to the registration of Bedaquiline.


Vision and Mission

Better healthcare starts with us. TASK provides a platform for the development of novelties in healthcare that benefit the community.


We want to be excellent. Do our work right and on time, every time. We own up, learn, and improve each day. We are TASK.


The Western Cape is home to diverse population groups, this coupled with first world infrastructure and TASK clinical expertise and experience, provides an ideal setting for clinical research.

We believe in community



Sisonke study successfully vaccinates more than 250 000 health workers before the third wave

Cape Town | Yesterday the Sisonke study reached 251 707 health workers marking its halfway point as it continues to move forward towards its target of vaccinating half a million of the country’s health workers. This unique effort, spearheaded by the South African Medical Research Council in partnership with the National Department of Health, Desmond Tutu…

Read more

Current Treatment Stand

Furthermore, TB is increasingly becoming resistant to the current treatment

New TB Drugs In The Pipeline

There are currently at least 12 drugs in various stages of clinical evaluation for TB

Clinical Studies

We do many clinical studies, click to read more about it.

Asthma Trials

We are looking for children and adults to participate.

TB Research

Tuberculosis is one of the major causes of disability and death worldwide.


Tuberculosis is one of the major causes of disability and death worldwide.
TB is currently the leading cause of death from a single infectious agent (above HIV/AIDS). In 2017, TB caused an estimated 1.6 million deaths worldwide. In the same year an estimated 10.0 million people developed TB globally (WHO Global TB report, 2018). South Africa remains one of the World Health Organization’s 30 high TB-burden countries contributing 3% to the global TB burden, with close to 800 people out of every 100 000 of the country’s population developing a new case of TB yearly (South African Health Review, 2018).
TB is a leading cause of death for people infected with HIV.
In 2015, 1 in 3 HIV deaths was due to TB. Globally in 2014, an estimated 480, 000 people developed multidrug-resistant TB (MDR-TB).
TASK is part of the global research community that is committed to finding new ways to better understand, diagnose, treat, and ultimately prevent TB.